| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Brodalumab |
| Brand | Kyntheum® |
| Indication | Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 25/07/2017 |
| Rapid review completed | 29/08/2017 |
| Rapid review outcome | Full pharmacoeconomic assessment recommended at submitted price |
The HSE has approved reimbursement following confidential price negotiations January 2018.